Selected article for: "cell culture and dose effect"
Author: Natalya Bukreyeva; Emily K. Mantlo; Rachel A. Sattler; Cheng Huang; Slobodan Paessler; Jerry Zeldis
Title: The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro
  • Document date: 2020_4_9
    • ID: geb4esu5_2
    Snippet: The effect is dose-dependent, and concentrations as low as 3.3 μM significantly reduced viral titers when the cells were pretreated prior to infection. The results of this study provide evidence that MMPD may be a viable treatment option for COVID-19. Drugs with history of being tested in human patients or used for treatment of other conditions offer the most expedient option, and several such drugs are currently being tested for efficacy agains.....
    Document: The effect is dose-dependent, and concentrations as low as 3.3 μM significantly reduced viral titers when the cells were pretreated prior to infection. The results of this study provide evidence that MMPD may be a viable treatment option for COVID-19. Drugs with history of being tested in human patients or used for treatment of other conditions offer the most expedient option, and several such drugs are currently being tested for efficacy against SARS-CoV-2, including many broad-spectrum antivirals. One such antiviral, merimepodib (MMPD), has already being tested against hepatitis C in patients as well as against many emerging RNA viruses in cell culture, including Zika, Ebola, Lassa, Junin, and . CC-BY-NC-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.07.028589 doi: bioRxiv preprint chikungunya viruses (1) . MMPD noncompetitively inhibits inosine-5'-monophosphate dehydrogenase (IMPDH), an enzyme responsible for de novo synthesis of guanosine nucleotides (2, 3) . In vitro, inhibition can be reversed by addition of exogenous guanosine (4).

    Search related documents:
    Co phrase search for related documents
    • guanosine nucleotide and treatment option: 1
    • human patient and low concentration: 1, 2, 3
    • human patient and RNA virus: 1, 2, 3, 4, 5, 6, 7, 8
    • RNA virus and SARS efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • RNA virus and significantly reduce: 1, 2, 3
    • RNA virus and treatment option: 1, 2, 3, 4, 5, 6
    • RNA virus and viable treatment option: 1
    • RNA virus and viral titer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • SARS efficacy and significantly reduce: 1, 2, 3, 4, 5, 6, 7, 8
    • SARS efficacy and study result: 1
    • SARS efficacy and treatment option: 1, 2, 3, 4, 5, 6, 7
    • SARS efficacy and viable treatment option: 1, 2, 3
    • SARS efficacy and viral titer: 1, 2, 3, 4
    • SARS efficacy test and viral titer: 1
    • significantly reduce and study result: 1, 2
    • significantly reduce and treatment option: 1, 2, 3
    • significantly reduce and viral titer: 1, 2
    • treatment option and viable treatment option: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63
    • treatment option and viral titer: 1